Definitive Healthcare Corp.
Definitive Healthcare Corp. (DH) Financial Performance & Income Statement Overview
Review Definitive Healthcare Corp. (DH) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Definitive Healthcare Corp. (DH) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Definitive Healthcare Corp. DH financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $59.19M | $62.29M | $62.70M | $63.74M |
| Cost of Revenue | $15.43M | $14.69M | $13.67M | $22.69M |
| Gross Profit | $43.76M | $47.60M | $49.03M | $41.05M |
| Gross Profit Ratio | $0.74 | $0.76 | $0.78 | $0.64 |
| R&D Expenses | $9.30M | $8.98M | $7.28M | $10.12M |
| SG&A Expenses | $32.92M | $28.88M | $31.48M | $34.07M |
| Operating Expenses | $228.55M | $147.16M | $274.40M | $44.19M |
| Total Costs & Expenses | $243.98M | $161.85M | $288.06M | $66.89M |
| Interest Income | $2.05M | $3.21M | $3.74M | $3.72M |
| Interest Expense | $2.43M | $3.51M | $3.75M | $3.76M |
| Depreciation & Amortization | $13.82M | $13.13M | $13.06M | $12.79M |
| EBITDA | -$90.25M | -$73.97M | -$111.45M | -$311.54M |
| EBITDA Ratio | -$1.52 | -$1.19 | -$1.78 | -$4.89 |
| Operating Income | -$184.79M | -$99.56M | -$225.37M | -$3.15M |
| Operating Income Ratio | -$3.12 | -$1.60 | -$3.59 | -$0.05 |
| Other Income/Expenses (Net) | $18.81M | $8.95M | $23.82M | $41.55M |
| Income Before Tax | -$165.98M | -$90.61M | -$201.55M | -$328.09M |
| Income Before Tax Ratio | -$2.80 | -$1.45 | -$3.21 | -$5.15 |
| Income Tax Expense | -$10.89M | -$5.89M | -$13.72M | -$21.90M |
| Net Income | -$107.23M | -$59.08M | -$130.90M | -$213.63M |
| Net Income Ratio | -$1.81 | -$0.95 | -$2.09 | -$3.35 |
| EPS | -$0.95 | -$0.51 | -$1.12 | -$1.81 |
| Diluted EPS | -$0.95 | -$0.51 | -$1.12 | -$1.81 |
| Weighted Avg Shares Outstanding | $112.78M | $115.02M | $116.38M | $117.75M |
| Weighted Avg Shares Outstanding (Diluted) | $112.78M | $115.02M | $116.38M | $117.75M |
Financial performance has remained strong, with revenue growing from $63.74M in Q2 2024 to $59.19M in Q1 2025. Gross profit continued to perform well, with margins at 74% in the latest quarter. Operating income reached -$184.79M in Q1 2025, holding a steady -312% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$90.25M. Net income dropped to -$107.23M, keeping EPS at -$0.95. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan